Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Bayer.

Oncology Brothers Drs Rahul and Rohit Gosain facilitate a podcast discussion between medical oncologist Prof Tanios Bekaii-Saab and Deneen Richmond, a patient advocate and healthcare executive who has herself experienced rectal cancer.

 

Together, they look at how to manage the needs of different patient populations with colorectal cancer, focusing on age, ethnicity, socioeconomic status, and access to healthcare.  The experts share their own experiences of practising oncology and surviving cancer.

 

The speakers discuss a range of topics, including:

  • Education and awareness needs of different ethnic groups such as African Americans, Hispanics and Asian Americans and the importance of building trust within these populations
  • The unique needs of younger patients and the challenges they face, such as managing work, caring for family members and children
  • The importance of encouraging screening leading to early diagnosis in these patient groups

 

Clinical takeaways

  • Understanding the diverse needs of different patient populations with colorectal cancer is crucial for delivering effective care.
  • Disparities in access to healthcare services and quality of care exist among different patient populations.
  • Healthcare inequities can be addressed by promoting education and awareness and ensuring culturally sensitive care delivery for all patient populations.
  • Collaboration through patient and caregiver advocates and trusted members of the community can improve overall healthcare quality.

Understanding the needs of different patient populations in colorectal cancer: Educational objectives

  • To help healthcare professionals understand the needs of different ethnicities and other specific patient groups in colorectal cancer and how to address them

Tanios Bekaii-Saab, MD is a Professor of Medicine at the Mayo Clinic College of Medicine and Science. He is the Chair for Hematology and Medical Oncology for the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona, USA. He is the leader of the Gastrointestinal Cancer for the Enterprise-wide Mayo Clinic Cancer Center Dr. Bekaii-Saab is currently the co-leader of the Hepatobiliary Cancer Sub-Committee of the Alliance for Clinical Trials in Oncology and the Co-Chair for the National Cancer Institute’s Hepatobiliary Task Force.

 

Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.


Dr. Bekaii-Saab served as a reviewer for many high impact journals and sits on the editorial board of the prestigious Journal of the National Cancer Institute. Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters, including papers in such journals as New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

Prof. Tanios Bekaii-Saab has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS. Consulting (to institution): Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA and Merck. Consulting (to self): Stemline, AbbVie, Blueprint Medicines , Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine and Sanofi. Glaxo SmithKline , Xilio. IDMC/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan and 1Globe.  Scientific Advisory Board: Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma. Royalties: Uptodate. Inventions/Patents: WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene, WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion

In February 2023, Deneen Richmond’s life was forever changed when she was diagnosed with Stage 3 rectal cancer. After a year of treatment including chemotherapy, chem-radiation and surgery, Ms. Richmond is proud to shout from the rooftops that she has no evidence of disease. Deneen has shared her personal journey in many forums, and is dedicated to being a patient advocate, erasing the stigma and educating others about colorectal cancer. Deneen is also passionate about improving the health of our communities, promoting health equity and eradicating health disparities.


Deneen has more than 30 years of healthcare leadership experience and currently is the president of a 200+ bed community hospital in Maryland. She has a bachelor’s degree in nursing from the University of the District of Columbia and a master’s degree in health care administration from The George Washington University. She is the author of two chapters in The Healthcare Quality Book, fifth edition, published in 2023 – Health Equity and Diversity; and Population Health. Deneen serves as adjunct faculty at the George Washington University, Milken School of Public Health in the executive masters in health administration programme. She has received numerous professional awards and recognitions.


Deneen uniquely brings the perspective as a patient advocate, a registered nurse and an accomplished healthcare executive. Her most important experience comes from being a patient as a person diagnosed with cancer.

Drs. Rohit Gosain and Rahul Gosain, the Oncology Brothers, are board certified in internal medicine, hematology, and oncology. They work in the community setting as generalists, and their mission is to bridge the gap between the community and academia by providing key insights and succinct conference updates, discussing practice-changing data, and reiterating the standard of care.

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre.  

Meet the experts

Other programmes of interest

podcast Podcast
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024

video Video
Oncology Hemato-oncology 
Early relapsed/refractory multiple myeloma (RRMM): best practices in management

A 3-part video series on managing early RRMM from leading medical experts

Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2024

other Other

Episode

2

of 2

episode
Oncology 
Optimising samples for biomarker testing in lung, prostate and gastric cancer

Recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Aug 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
publication Publication
Oncology 
Advancing HCC management in Asia: insights from patients and HCPs

Paper published in Journal of Gastrointestinal Cancer

Experts
Prof. Chee-Kiat Tan
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Jul 2024

This educational programme is supported by an Independent Educational Grant from Roche.
other Other
Oncology 
Come and visit us in Barcelona at ESMO 2024!

Get your free professional profile photos taken with us at Booth 507

  • clock 1 MIN
  • calendar Jul 2024

micro-learning Micro learning
Oncology Endocrinology Rare diseases 
Tools for optimising treatment & management of advanced NETs

Maximising outcomes for patients with advanced neuroendocrine tumours 

Experts
Prof. Emily Bergsland, Prof. Louis de Mestier
Endorsed by
NANETS
Neuroendocrine Cancer UK
CommNETs
The Healing NET Foundation
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Educational Grant from Ipsen.